Co-Authors
This is a "connection" page, showing publications co-authored by Giordano Madeddu and Paolo Bonfanti.
Connection Strength
0.774
-
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project. Infect Drug Resist. 2019; 12:1385-1391.
Score: 0.206
-
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. AIDS. 2017 01 28; 31(3):455-457.
Score: 0.176
-
Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study. Curr HIV Res. 2010 Mar; 8(2):165-71.
Score: 0.109
-
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. New Microbiol. 2019 Jul; 42(3):150-155.
Score: 0.052
-
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
Score: 0.049
-
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infect Drug Resist. 2018; 11:615-623.
Score: 0.048
-
Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infect Dis. 2017; 4(4):ofx239.
Score: 0.046
-
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
Score: 0.045
-
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study. J Hypertens. 2017 02; 35(2):409-416.
Score: 0.044